Prevention and early detection of vascular complications of diabetes

British Medical Journal

Volumn 333, Issue 7566, 2006, Pages 475-480

  Marshall, Sally M ^a   Flyvbjerg, Allan ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ARTERY DISEASE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TOLERANCE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIFESTYLE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOPATHY; REVIEW; RISK FACTOR; SMOKING; VASCULAR DISEASE; VISUAL ACUITY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MASS SCREENING; RISK FACTORS;

EID: 33748429057     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38922.650521.80     Document Type: Review

References (26)

1. Jonsson B. CODE-2 advisory board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5-12.
2. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al. The British Diabetic Association cohort study II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabetic Med 1999;16:466-71.
3. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
4. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005;48:1439-44.
5. US Renal Data System. USRDS 2005 annual data report. Bethesda, MD: National Institute of Health, National Institute of Diabetes, Digestive and Kidney Disease, 2005 (www.usrds.org/adr.htm).
6. Van Dijk PC, Jager KJ, Dtengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67:1489-99.
7. Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005;48:805-7.
8. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.
9. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010.
10. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
12. UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
13. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type I diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003;290:2159-67.
14. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al. DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetic Care 2006;29:340-4.
15. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
16. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.
17. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
19. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005;4:CD004136.
20. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al, CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
22. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24.
23. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al, FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
24. National Institute for Clinical Excellence. Clinical guideline 10; type 2 diabetes. Prevention and management of foot problems. National Institute for Clinical Excellence 2004 (www.NICE.org.uk/CGO10NICEguideline).
25. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
26. Reiber GE, Raugi GJ. Preventing foot ulcers and amputations in diabetes. Lancet 2005;366:1676-7.